Clinical perspective of afatinib in non-small cell lung cancer

Lung Cancer

Volumn 81, Issue 2, 2013, Pages 155-161

  Chen, Xiaofeng ^a   Zhu, Quan ^a   Zhu, Lingjun ^a   Pei, Dong ^a   Liu, Yiqian ^a   Yin, Yongmei ^a   Schuler, Martin ^b   Shu, Yongqian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Acquired resistance; Afatinib; Epthelial growth factor receptor; Non small cell lung cancer; Tyrosine kinase inhibitior

Indexed keywords

AFATINIB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; PEMETREXED;

ACNE; CANCER CHEMOTHERAPY; CELL TRANSDIFFERENTIATION; DECREASED APPETITE; DIARRHEA; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NAIL DISEASE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMATITIS;

ACQUIRED RESISTANCE; AFATINIB; EPTHELIAL GROWTH FACTOR RECEPTOR; NON-SMALL CELL LUNG CANCER; TYROSINE KINASE INHIBITIOR;

CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84879884454     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.02.021     Document Type: Review

References (49)

1. Soria J.C., Mok T.S., Cappuzzo F., Janne P.A. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer Treat Rev 2012, 38:416-430.
2. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
3. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
4. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
5. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3. 75ra26.
6. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008, 105:2070-2075.
7. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005, 102:7665-7670.
8. Cohen M.S., Zhang C., Shokat K.M., Taunton J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 2005, 308:1318-1321.
9. Garuti L., Roberti M., Bottegoni G. Irreversible protein kinase inhibitors. Curr Med Chem 2011, 18:2981-2994.
10. Engelman J.A., Zejnullahu K., Gale C.M., Lifshits E., Gonzales A.J., Shimamura T., et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007, 67:11924-11932.
11. Li D., Ambrogio L., Shimamura T., Kubo S., Takahashi M., Chirieac L.R., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711.
12. Rabindran S.K., Discafani C.M., Rosfjord E.C., Baxter M., Floyd M.B., Golas J., et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004, 64:3958-3965.
13. Solca F., Dahl G., Zoephel A., Bader G., Sanderson M., Klein C., et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012, 343:342-350.
14. Eskens F.A., Mom C.H., Planting A.S., Gietema J.A., Amelsberg A., Huisman H., et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 2008, 98:80-85.
15. Lewis N.J.M., Amelsberg A., Cohen R.B., Stopfer P., Hwang J., Malik S. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors. J Clin Oncol 2006, 18S.
16. Yap T.A., Vidal L., Adam J., Stephens P., Spicer J., Shaw H., et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010, 28:3965-3972.
17. Murakami H., Tamura T., Takahashi T., Nokihara H., Naito T., Nakamura Y., et al. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother Pharmacol 2012, 69:891-899.
18. Stopfer P., Marzin K., Narjes H., Gansser D., Shahidi M., Uttereuther-Fischer M., Ebner T. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol 2012, 69:1051-1061.
19. Carmi C., Mor M., Petronini P.G., Alfieri R.R. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem Pharmacol 2012, 84:12.
20. Miller V.A., Hirsh V., Cadranel J., Chen Y.M., Park K., Kim S.W., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012, 13:528-538.
21. Yang J.C., Shih J.Y., Su W.C., Hsia T.C., Tsai C.M., Ou S.H., et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012, 13:539-548.
22. Yang J.C.-H., Schuler M.H., Yamamoto N., O'Byrne K.J., Hirsh V., Mok T., Geater S.L., et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 2012, 30. (abstr LBA7500).
23. Martin H., Schuler D.P., Yang J.C.-H., Kim J.-H., De Marinis F., Chen Y.-M., et al. Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator's choice chemotherapy following progression on afatinib monotherapy. J Clin Oncol 2012, 30. (abstr 7557).
24. Kim F.G.J.-H., De Marinis F., Cobo M., Yang J.C.-H., Ragulin Y., Bondarenko I.N., et al. Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: interim subset analysis from a phase III trial. J Clin Oncol 2012, 30. (abstr 7558).
25. Jackman D., Pao W., Riely G.J., Engelman J.A., Kris M.G., Janne P.A., et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010, 28:357-360.
26. Yamamoto N.N.K., Atagi S., Hida T., Goto K., Horai T., Inoue A., et al. A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G). J Clin Oncol 2012, 29. (abstr 7524).
27. Han J.Y., Park K., Kim S.W., Lee D.H., Kim H.Y., Kim H.T., et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012, 30:1122-1128.
28. Inoue A., Kobayashi K., Maemondo M., Sugawara S., Oizumi S., Isobe H., et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013, 24:54-59.
29. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
30. Janne P.A., Wang X., Socinski M.A., Crawford J., Stinchcombe T.E., Gu L., et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol 2012, 30:2063-2069.
31. Köhler J.K.W., Gauler T.C., Hoiczyk M., Theegarten D., Eberhardt W., Hense J., et al. Impact of egfr mutation status on clinical benefit from bibw 2992 in patients (pts) with advanced Non-small cell lung cancer (NSCLC) progressing after chemotherapy (ctx) and erlotinib (E) or gefitinib (G) - a single center experience. Ann Oncol 2012, 23(Suppl 9). abstr1339.
32. Ahn M.A.K.S., Cho B., Ahn J.S., Lee D.H., Sun J., Massey D., et al. Phase II trial of afatinib as a third-line treatment for Korean patients (pts) with wild-type epidermal growth factor receptor (wtEGFR) stage IIIB/IV lung adenocarcinoma. Ann Oncol 2012, 23(Suppl 9). (abstr 1292P).
33. Yang J.C.M.S., Yamamoto N., O.' Byrne K.J., Hirsh V., Mok T.S.K., Massey D.V.Z., et al. Activity of afatinib in uncommon epidermal growth factor receptor (egfr) mutations in Lux-lung 3, a phase iii trial of afatinib or cisplatin/pemetrexed in egfr mutation-positive lung cancer. Ann Oncol 2012, 23(suppl 9). (abstr 1252P).
34. Won Y.W., Han J.Y., Lee G.K., Park S.Y., Lim K.Y., Yoon K.A., et al. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. J Clin Pathol 2011, 64:947-952.
35. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
36. Yang C.H., Yu C.J., Shih J.Y., Chang Y.C., Hu F.C., Tsai M.C., et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008, 26:2745-2753.
37. Sequist L.V., Besse B., Lynch T.J., Miller V.A., Wong K.K., Gitlitz B., et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:3076-3083.
38. Kim Y., Ko J., Cui Z., Abolhoda A., Ahn J.S., Ou S.H., et al. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther 2012, 11:784-791.
39. Ercan D., Zejnullahu K., Yonesaka K., Xiao Y., Capelletti M., Rogers A., et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010, 29:2346-2356.
40. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
41. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007, 104:20932-20937.
42. Chakravarti A., Loeffler J.S., Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002, 62:200-207.
43. Matar P., Rojo F., Cassia R., Moreno-Bueno G., Di Cosimo S., Tabernero J., et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 2004, 10:6487-6501.
44. Huang S., Armstrong E.A., Benavente S., Chinnaiyan P., Harari P.M. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004, 64:5355-5362.
45. Janjigian Y.Y., Azzoli C.G., Krug L.M., Pereira L.K., Rizvi N.A., Pietanza M.C., et al. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res 2011, 17:2521-2527.
46. Regales L.G.Y., Shen R., de Stanchina E., Vivanco I., Goel A., Koutcher J.A., et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009, 119:3000-3010.
47. Janjigian Y.Y.H.J.G., Horn L., Smit E.F., Fu Y., Wang F., Shahidi M., et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 2012, 29. (abstr 7525).
48. Takezawa K., Okamoto I., Tanizaki J., Kuwata K., Yamaguchi H., Fukuoka M., et al. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther 2010, 9:1647-1656.
49. Quincy C.R.S., Hotte S.J., Deng Q., Gyorffy S., Chand V.K., Hirte H.W. Once-daily oral afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: a phase I dose escalation trial. J Clin Oncol 2012, 30. (abstr e13011).